L
Libero Santarpia
Researcher at University of Texas MD Anderson Cancer Center
Publications - 86
Citations - 5283
Libero Santarpia is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 36, co-authored 79 publications receiving 4617 citations. Previous affiliations of Libero Santarpia include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
TL;DR: Inhibitors of MEK and particularly of RAF kinases have shown effectiveness in clinical trials with manageable side effects and need to be analyzed for mutations as markers of response to treatments and to avoid paradoxical effects.
Journal ArticleDOI
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
András Lánczky,Ádám Nagy,Giulia Bottai,Gyöngyi Munkácsy,András Szabó,Libero Santarpia,Balázs Győrffy +6 more
TL;DR: An integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer is established.
Journal ArticleDOI
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun-Jung Jung,Eun-Jung Jung,Libero Santarpia,Ju-Yeon Kim,Francisco J. Esteva,Erica Moretti,Aman U. Buzdar,Angelo Di Leo,Xiao Feng Le,Robert C. Bast,Soon Tae Park,Lajos Pusztai,George A. Calin +12 more
TL;DR: The authors of this report hypothesized that altered miR expression levels in plasma are associated with sensitivity to trastuzumab in patients with HER‐2 positive breast cancer.
Journal ArticleDOI
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
Takayuki Iwamoto,Giampaolo Bianchini,Daniel J. Booser,Yuan Qi,Charles Coutant,Christine Y. Shiang,Libero Santarpia,Junji Matsuoka,Gabriel N. Hortobagyi,William Fraser Symmans,Frankie A. Holmes,Joyce O'Shaughnessy,Beth A. Hellerstedt,John Pippen,Fabrice Andre,Richard Simon,Lajos Pusztai +16 more
TL;DR: Different biological processes were associated with prognosis and chemotherapy response in ER-positive and ER-negative breast cancers.
Journal ArticleDOI
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
TL;DR: BRAF mutations appear to play a role in the tumorigenesis of a subset of ATCs, and the majority of lymph node metastases, while PIK3CA alterations occur preferentially in the later stages of A TC and were the most relevant events during thyroid cancer progression.